Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nagoya Firm Discovers A System To Deliver Drugs Into Brain

This article was originally published in PharmAsia News

Executive Summary

Nagoya-based Tissue Targeting Japan Inc. has developed the T2J peptide, a synthetic molecule that is able to permeate the blood-brain barrier and deliver drugs and materials directly inside human brains. Until now, the blood-brain barrier has blocked viruses and toxins as well as drugs from entering the brain. The T2J research team discovered that the microglial cell, a certain kind of glial cell, which accounts for 90 percent of brain cells, has the ability to permeate the brain blood barrier. Modeled after the microglial cell's movement pattern inside the brain, the T2J peptide can deliver chemicals directly to the brain. Tissue Targeting Japan will strengthen joint research with pharmaceutical companies and expects to launch a new drug using the peptide in 2015. (Click here for more-Japanese language

You may also be interested in...

European Commission Decides CBD Is Not A Drug Opening Up Novel Food Pathway

The European Commission has unexpectedly concluded that CBD should not be considered as drug opening up the path to regulated EU market for the cannabinoid as a novel food.

Who’s Hired? Apotex Names New US President & CEO

As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles. 

UN Rejects Proposal To Exempt CBD From International Narcotics Controls

A WHO recommendation to explicitly exempt low-THC CBD from international narcotics controls has been emphatically rejected by UN member states. The CBD industry had hoped for a positive outcome to remove regulatory pressure on product manufacturers in Europe and around the world. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts